Recursion Pharmaceuticals, Inc. (RXRX)

Recursion (RXRX) is a cash-rich but loss-making clinical-stage biotech. FY2025 revenue was $74.68M (+26.92% YoY), but profitability remained deeply negative (FY2025 EBITDA -$559.38M; FY2025 free cash flow -$378.28M). Liquidity is solid (TTM current ratio ~5.47; the 10-Q filed 2026-05-06 reports cash and cash equivalents of ~$654.5M and states this should fund operations for at least 12 months), and the 10-K filed 2026-02-25 contains no explicit going-concern qualification. However, SEC risk factors highlight the need for additional financing and high clinical/regulatory uncertainty, and the 10-Q discloses material weaknesses in internal controls tied to acquired operations. With EV/Sales ~17.93x and a -18.40% free-cash-flow yield (cash burn), RXRX screens as a high-risk, expectation-driven equity. fundamentalScore: 2/5.

Recent coverage turned bullish versus a near-neutral 30–90d baseline, driven mainly by announced Russell index additions and renewed momentum/“inflection point” headlines. With no first-party GlobeNewswire PR catalysts surfaced and no regulator-confirmed legal overhang, the setup is constructive but largely flow/tape-driven and likely only partially priced.

RXRX looks technically strong on a short-term basis: price is above SMA20/SMA50, EMA9/EMA21, and the latest session VWAP, MACD is positive and above signal, RSI14 is 67.3, and ADX14 at 30.94 confirms a real directional move rather than a weak bounce. Volume supports the move with 20-day average dollar volume of 77164282.78 and a much hotter last three sessions, but the chart still has two blemishes: price is still pressing into the 200-day SMA near 4.1 and ATR14 is about 6.8% of price, so the tape remains volatile.